Studies designed to investigate possible treatments or cures for DMD commonly utilize the mdx mouse as a preclinical model to examine if the pharmaceutical or genetic intervention strategies prevent or reduce this EC force loss in dystrophin deficient fast-twitch skeletal muscle (Welch et al., 2007; Blaauw et al., 2008; Piers et al., 2011; Tinsley et al., 2011; Selsby et al., 2012; Aartsma-Rus and Muntoni, 2013; Fairclough et al., 2013; Rodino-Klapac et al., 2013; Roy et al., 2016). Here, DMD is linked to Duchenne muscular dystrophy.